Taro Pharmaceutical Industries (TARO) Stock Forecast, Price & News

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Taro Pharmaceutical Industries in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" TARO shares.
View TARO analyst ratings or view top-rated stocks.

1 equities research analysts have issued twelve-month target prices for Taro Pharmaceutical Industries' shares. Their TARO share price forecasts range from $35.00 to $35.00. On average, they expect the company's share price to reach $35.00 in the next year. This suggests that the stock has a possible downside of 7.2%.
View analysts price targets for TARO or view top-rated stocks among Wall Street analysts.

Taro Pharmaceutical Industries' stock was trading at $29.04 at the beginning of the year. Since then, TARO stock has increased by 29.9% and is now trading at $37.71.
View the best growth stocks for 2023 here.

Taro Pharmaceutical Industries saw a decline in short interest in the month of September. As of September 15th, there was short interest totaling 256,800 shares, a decline of 35.6% from the August 31st total of 398,600 shares. Based on an average trading volume of 43,400 shares, the short-interest ratio is presently 5.9 days. Currently, 3.2% of the shares of the stock are sold short.
View Taro Pharmaceutical Industries' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Thursday, October 26th 2023.
View our TARO earnings forecast.

Taro Pharmaceutical Industries Ltd. (NYSE:TARO) issued its quarterly earnings data on Wednesday, July, 26th. The company reported $0.40 EPS for the quarter, beating the consensus estimate of $0.31 by $0.09. The business had revenue of $158.89 million for the quarter, compared to analyst estimates of $149 million. Taro Pharmaceutical Industries had a trailing twelve-month return on equity of 1.52% and a net margin of 3.72%.

ARK Israel Innovative Technology ETF holds 58,404 shares of TARO stock, representing 2.19% of its portfolio.

11 employees have rated Taro Pharmaceutical Industries Chief Executive Officer Uday Baldota on Glassdoor.com. Uday Baldota has an approval rating of 19% among the company's employees. This puts Uday Baldota in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Taro Pharmaceutical Industries investors own include Gilead Sciences (GILD), Bausch Health Companies (BHC), Broadcom (AVGO), Pfizer (PFE), Teva Pharmaceutical Industries (TEVA), Skyworks Solutions (SWKS), GW Pharmaceuticals (GWPH), Delta Air Lines (DAL), Jazz Pharmaceuticals (JAZZ) and Southwest Airlines (LUV).

Taro Pharmaceutical Industries trades on the New York Stock Exchange (NYSE) under the ticker symbol "TARO."

Shares of TARO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of TARO stock can currently be purchased for approximately $37.71.

Taro Pharmaceutical Industries (NYSE:TARO) has a market capitalization of $1.42 billion and generates $572.95 million in revenue each year. The company earns $25.44 million in net income (profit) each year or $0.57 on an earnings per share basis.

The company employs 1,554 workers across the globe.

Taro Pharmaceutical Industries' mailing address is 14 HAKITOR ST PO BOX 10347, HAIFA BAY L3, 10532. The official website for the company is www.taro.com. The company can be reached via phone at (724) 847-5700, via email at investorrelations@taro.com, or via fax at 914-345-6169.